

## Talius Group selected for the BEDA MedTech Initiative Global Accelerator

4 August 2025

### HIGHLIGHTS

- Talius selected for Brisbane Economic Development Agency's (BEDA's) MedTech Initiative: Global Accelerator
- The program is to assist early-stage ventures with transformative opportunity to scale globally
- Exposure to key government agencies and investors, including presenting at the Redefining Early-Stage Investment (RESI) Conference as part of J.P. Morgan Healthcare Week in San Francisco

**Talius Group Limited (Talius or the Company) (ASX: TAL)** is pleased to announce it has been selected by BEDA for the MedTech FY26 Global Accelerator.

### The MedTech Global Accelerator

The MedTech Global Accelerator program is a prestigious initiative by BEDA designed to accelerate global investment opportunities for early-stage health and medical technology ventures. Through a structured series of modules, the accelerator will offer Talius access to international capital, joint product collaboration opportunities, and global licensing and distribution networks, supported by experienced mentors from leading multinational corporations including Johnson & Johnson, Medtronic, Pfizer, Sanofi, and Stryker.

The accelerator program will culminate in a global mission to San Francisco, USA, during the J.P. Morgan Healthcare Week in January 2026. This high-profile event provides Talius with an international platform to launch funding campaigns, engage with global investors, and showcase innovative solutions through dedicated pitch sessions, forums, and targeted one-on-one meetings.

### Comments from the Managing Director, Graham Russell

*"We are delighted to have been selected for this prestigious program. Participation in the MedTech Global Accelerator represents a significant milestone and recognition of Talius' innovative solutions within the health technology sector. This opportunity will provide invaluable exposure to international markets and investors and strongly aligns with our strategic objectives to scale globally. We look forward to showcasing Talius at the J.P. Morgan Healthcare Week and capitalising on the opportunities presented by this program."*

This announcement has been authorised by the Board of Directors of Talius Group Limited.

**Investor Enquiries:**

Andrew Ritter

**Company Secretary**

1300 889 838

[investors@Talius.com.au](mailto:investors@Talius.com.au)**More on TALIUS**[Investor centre](#)[About Us](#)[News](#)**About Talius Group Limited (ASX: TAL)**

Talius provides a suite of technology enabled care solutions to the aged and disability sectors across multiple verticals, including retirement living, residential aged care, home, and community settings to improve the quality of life, later in life.

Talius' Software as a Service (SaaS) data analytics platform Talius Smart Care combines smart sensors with AI machine learning that delivers automated actions. Talius links awareness, analysis, and action through one platform allowing the care model to move from spot check care to sense-respond care. Nursing staff can switch their focus from data collection to building a human connection. Most importantly, residents benefit from a new era of autonomy and dignity.

Talius helps protect and connect our elderly and people with disabilities with a scalable healthcare technology platform integrated with leading third-party providers to ensure end-to-end solutions for Connected Health.

**FORWARD LOOKING STATEMENTS**

*Certain statements contained in this ASX release, including information as to the future financial or operating performance of the Company and its projects, are forward looking statements. Such forward looking statements:*

- (a) are necessarily based upon several estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political, and social uncertainties and contingencies;*
- (b) involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward looking statements; and*
- (c) may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results, and capital expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social, and other conditions. The Company disclaims any intent or obligation to publicly update any forward-looking statements, whether because of new information, future events, or results or otherwise.*

*The words "believe", "expect", "contracted", "anticipate", "indicate", "contemplate", "target", "plan", "intends", "continue", "budget", "estimate", "may", "will", "schedule", "planned" and similar expressions identify forward looking statements. All forward looking statements contained in this ASX release are qualified by the foregoing cautionary statements. Recipients are cautioned that forward looking statements are not guarantees of future performance and accordingly recipients are cautioned not to put undue reliance on forward looking statements due to the inherent uncertainty therein.*